Alkermes Granted Orphan Drug Designations for Alixorexton in US, Europe
The investigational oral orexin 2 receptor agonist received designations from the FDA for idiopathic hypersomnia and the European Commission for narcolepsy.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
